Fractional laser plus exosome vs. laser plus placebo for androgenetic alopecia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Participants with male-pattern baldness (Norwood-Hamilton types III–V) will receive three sessions of fractional laser treatment and be randomized to receive either the exosome solution or a placebo alongside the laser. The trial will follow 30 men aged 18 to 50 for 6 months, monitoring hair density, hair diameter, the ratio of vellus to terminal hairs, and adverse events, with standardized photographs for assessment. Safety, tolerability, and preliminary efficacy signals will be evaluated through clinical and imaging endpoints. The study is conducted at Chang Gung Memorial Hospital Taoyuan, in collaboration with ExoOne bio.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Male pattern baldness diagnosed according to the Norwood-Hamilton classification III-V
2. Males aged 18 to 50 years
3. Willing to provide written informed consent and possessing the ability to read, write, speak, and understand
4. Able to follow the study's treatment guidelines

Exclusion Criteria:

1. Those who have taken oral Finasteride, Dutasteride, or Minoxidil within 6 months prior to the start of the trial.
2. Those who have used any topical or systemic medications that may affect hair growth within 6 months prior to the start of the trial.
3. Those who have received phototherapy, laser therapy, exosome therapy, or hair regrowth injections (such as minimally invasive procedures) within 6 months prior to the start of the trial.
4. Those with a history of hair transplant surgery.
5. Those suffering from other systemic or scalp diseases that may affect hair growth (e.g., iron deficiency anemia, immune disorders, thyroid diseases, and syphilis).
6. Those with a history of severe inflammation, keloids, malignant tumors, or poor wound healing at the treatment site.
7. Those with other diseases that make them unsuitable for fractional laser treatment.
8. Those with a history of malignant tumors or currently undergoing treatment.
9. Participants must not undergo any cosmetic procedures that may affect scalp condition or hair growth throughout the entire trial period, including hair dyeing, perming, bleaching, scalp exfoliation, deep scalp cleansing, or any other actions that may irritate or damage the scalp.

Where it's running

• Chang Gung Memorial Hospital Taoyuan branch
  Taoyuan, Taoyuan, Taiwan Recruiting

Study contacts

• Study coordinator: Chun-Yu Cheng, MD
• Email: dermatology99999@gmail.com
• Phone: +88633196200

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PP405 0.05% topically applied gel for adult men with pattern hair loss

  A topical gel called PP405 is being tested in adult men with androgenetic alopecia to see if it can help with hair growth and is safe over a year.

  Recruiting at 34 sites Phase 2/3 Pelage Pharmaceuticals, Inc. · Birmingham, Alabama and 62 other locations · NCT07819435

• EPI-001 for androgenetic alopecia in adults

  This early-phase study tests autologous dermal papilla cell therapy (EPI-001) to see if it is safe and can help hair grow in people with androgenetic alopecia.

  Recruiting Phase 1/2 Epibiotech · Seoul, Seoul · NCT07618195

• JAK2 levels in balding and non-balding scalp before and after topical minoxidil

  This will test whether three months of topical minoxidil changes JAK2 protein levels in the scalps of adults (18–50) with mild to moderate androgenetic alopecia.

  Recruiting Kasr El Aini Hospital · Cairo, Cairo Governorate · NCT07563036

• Secretome versus PRP injections to improve hair density in androgenetic alopecia

  This will try secretome injections versus platelet-rich plasma (PRP) injections to see which more effectively increases hair density and the terminal-to-vellus hair ratio in adults with androgenetic alopecia.

  Recruiting Phase 1/2 PT. Prodia Stem Cell Indonesia · Denpasar, Bali · NCT07429253

• Once-daily 5% minoxidil foam for female pattern hair loss

  This will try once-daily 5% minoxidil foam to see if it increases hair count in adult women with androgenetic alopecia compared with a placebo.

  Recruiting Phase 3 Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd. · Beijing · NCT07080931

• CKD-843 for male pattern baldness: a new treatment in Phase 3

  We’re testing CKD-843 in men aged 18–50 with androgenetic alopecia to see if it helps hair loss over 12 months.

  Recruiting Phase 3 Chong Kun Dang Pharmaceutical · Seoul · NCT06916793

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.